Current stock page

Stock Analysis

Omeros Corporation (OMER) Stock Analysis

Omeros Corporation (OMER) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

OMER Stock Analysis Summary

Omeros Corporation (OMER) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Risk is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

OMER at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$17.49
AIQ Score64/100
Overall ViewNeutral
Technical Analysis ConsensusSell
Market Cap$1.26B
P/E Ratio (TTM)9.16
Forward P/E—
EPS (Q2 FY2026)$0.18
Revenue (Q2 FY2026)$28.53M
Dividend Yield (TTM)0.00%
Beta1.6
Volume737.38K
52-week range$6.24-$21.24
RSI 1447.88
50-Day SMA$18.27
200-Day SMA$13.77
Analyst Price Target$22.00
Next EarningsNov 16, 2026
As of Nov 13, 2026 · Market close

OMEROmeros Corporation

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$17.49−$0.50 (−2.78%)

Latest quote

  • Momentum
    79
  • Value
    73
  • Quality
    55
  • Risk resilience
    33
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

OMER Stock Analysis Summary

Omeros Corporation (OMER) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Risk resilience is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, OMER has AIQ Score of 64/100 with Momentum base of 79/100 and fading Risk resilience at 33/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (79/100) leads while Risk resilience (33/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.78% stock move · OMER classified in Biotechnology.

Current Evidence

NeutralOMER is in a neutral AIQ regime; Momentum is the strongest visible factor at 79/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is OMER Bullish or Bearish Right Now?

OMER currently has a neutral overall setup. Momentum is the strongest factor at 79/100, while Risk Resilience is weakest at 33/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 79/100.
  • - Analyst target implies +25.79% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 33/100.
  • - Technical consensus has more sell votes than buy votes (27 vs 11).

Current Consensus

OMER's Technical Analysis Consensus is currently Sell, with 11 buy, 8 neutral, and 27 sell votes. OMER's 14-day RSI is 47.88, which places the stock in a neutral momentum range. OMER's beta is 1.6, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in OMER?

The largest recent change in OMER is Momentum moving down by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-5.0
Quality
+1.0
Risk
+1.0

What Would Change the OMER Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

OMER Decision Framework

Public evidence layers, setup checks, and risk context for Omeros Corporation.

Omeros Corporation (OMER) Stock Analysis

Omeros Corporation has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 79/100. Beta is 1.6, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextOMER is in a Neutral AIQ regime with score 64/100.
Signal ConflictThe primary conflict is that momentum leads at 79/100 while risk lags at 33/100.
Factor EvidenceMomentum 79/100 · Value 73/100 · Quality 55/100 · Risk 33/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 79/100.

TimingPass

Momentum is 79/100 and RSI (14) is 47.9.

Regime fitWait

OMER is in a Neutral regime at 64/100.

Risk controlFail

Risk factor is 33/100 with beta 1.6 and annual volatility 110.84%.

ConflictWait

Current conflict: momentum leads at 79/100 while risk lags at 33/100.

AIQ Score
64/100
Price
$17.49
Beta
1.6
RSI (14)
47.9

OMER Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

OMER Fundamentals

OMER valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$28.53M
Net income
$13.23M
Free cash flow
$4.1M
View full OMER fundamental analysis

OMER Technical Analysis

OMER technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
47.88
Price vs SMA-50
-4.25%
View full OMER technical analysis

OMER Stock Catalysts

Track OMER earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Nov 16, 2026
Analyst target
$22.00
News items
5
View OMER earnings and stock catalysts

OMER Dividend Analysis

OMER dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View OMER dividend history and analysis

OMER Financial Data

OMER revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$28.53M
EPS
$0.18
Periods
8
View OMER financials

OMER Risk Analysis

OMER volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.6
Risk score
33/100
1Y volatility
110.84%
View OMER risk analysis

OMER Stock News

OMER stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read OMER stock news

OMER vs Biotechnology Peers

Current peer cohort: OMER · ONC · ORKA · PCVX · PGEN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
OMER
Current stock
64/10073/10079/10033/1001.36110.84%Current
ONC
BeOne Medicines AG
80/10071/10091/10072/1000.4234.16%OMER vs ONC
ORKA
Oruka Therapeutics, Inc.
77/100—81/10053/1002.2969.09%OMER vs ORKA
PCVX
Vaxcyte, Inc.
66/100—81/10053/1000.7956.19%OMER vs PCVX
PGEN
Precigen, Inc.
55/10063/10055/10031/1000.5785.43%OMER vs PGEN
Pairwise Compare links: ONC · ORKA · PCVX · PGENOMER vs ONCOMER vs ORKAOMER vs PCVXOMER vs PGENCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a OMER stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for OMER: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
9.16
As of Nov 13, 2026
Revenue growth
—
Gross margin
95.77%
Current debt / equity
-1.63
Latest quarterly evidence

Latest period Jun 30, 2026.

Review fundamentals
Quarter revenue
$28.53M
Quarter net income
$13.23M
Quarter free cash flow
$4.1M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
47.88
MACD
-0.1

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
33/100
Beta
1.6
Annual volatility
110.84%
Max drawdown
-49.52%

OMER Stock FAQ

What is OMER stock price today?

Omeros Corporation's current stock price is $17.49. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is OMER bullish or bearish right now?

OMER's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is OMER's market cap?

OMER's market cap is $1.26B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is OMER's current P/E ratio?

OMER's current P/E ratio is 9.16 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is OMER's RSI?

OMER's 14-day RSI is 47.88 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is OMER above its 50-day and 200-day moving averages?

OMER is -4.25% from its 50-day SMA and 27.04% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is OMER's next earnings date?

OMER's next earnings date is currently listed as Nov 16, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does OMER pay a dividend?

OMER's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.